Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1125-1134

  Kyrgidis, Athanassios ^a,b,c   Triaridis, Stefanos ^b   Vahtsevanos, Kostantinos ^a   Antoniades, Kostantinos ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Bisphosphonate; Breast cancer; Dental extraction; Denture; Ibandronate; Jaw; Osteonecrosis; Pamidronate; Prevention; Zoledronate

Indexed keywords

ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ZOLEDRONIC ACID;

APOPTOSIS; BONE MASS; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CIGARETTE SMOKING; DEBRIDEMENT; DENTAL CARE; DENTAL SURGERY; DRUG SAFETY; EARLY DIAGNOSIS; ESOPHAGITIS; FIBROBLAST; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INHIBITION KINETICS; JAW OSTEONECROSIS; KERATINOCYTE; MACROPHAGE; MANDIBLE RESECTION; MOUTH HYGIENE; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 70349850428     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.74     Document Type: Review

References (104)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Coleman RE. Risks and benefits of bisphosphonates. Br. J. Cancer 98(11), 1736-1740 (2008). • Well written review from Professor Coleman who first introduced bisphosphonates (BPs) into the oncology practice.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165-176 (2001).
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s-6249s (2006).
5. Martin J, Coleman R, Mundy G. VI Meeting on Cancer-Induced Bone Disease. Expert Rev. Anticancer Ther. 7(4), 461-464 (2007).
6. Coleman RE. The role of bisphosphonates in breast cancer. Breast 13(Suppl. 1), S19-S28 (2004).
7. Coleman RE, Guise TA, Lipton A et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin. Cancer Res. 14(20), 6387-6395 (2008).
8. Body J-J, Mancini I. Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev. Anticancer Ther. 3(2), 241-246 (2003). (Pubitemid 36503401)
9. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 10(2), 169-180 (2005). (Pubitemid 41031006)
10. Briest S, Wolff AC. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Rev. Anticancer Ther. 7(9), 1243-1253 (2007). (Pubitemid 47521020)
11. Baud'huin M, Duplomb L, Velasco CR, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev. Anticancer Ther. 7(2), 221-232 (2007). • Summarizes the actions of BPs in the osteoprotegerin (RANK-RANKL-OPG) triad, useful in the understanding of the pathophysiology of the drugs.
12. D'Amelio P, Grimaldi A, Di Bella S et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res. 23(3), 373-379 (2008). (Pubitemid 351304667)
13. Perifanis V, Vyzantiadis T, Tziomalos K et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassaemia. Ann. Hematol. 86(1), 23-30 (2007). (Pubitemid 46138314)
14. Martini G, Gennari L, Merlotti D et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40(2), 457-463 (2007). (Pubitemid 46054544)
15. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos. Int. 17(5), 693-703 (2006).
16. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol. 19(8), 1407-1416 (2008).
17. Krempien R, Niethammer A, Harms W, Debus J. Bisphosphonates and bone metastases: current status and future directions. Expert Rev. Anticancer Ther. 5(2), 295-305 (2005). (Pubitemid 40553094)
18. Saad F, Adachi JD, Brown JP et al. Cancer treatment-induced bone loss in breast and prostate cancer. J. Clin. Oncol. 26(33), 5465-5476 (2008).
19. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev. Anticancer Ther. 8(9), 1377-1385 (2008).
20. Edwards BJ, Gounder M, McKoy JM et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 9(12), 1166-1172 (2008).
21. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J. Natl Cancer Inst. 99(13), 1016-1024 (2007).
22. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61(9), 1115-1117 (2003).
23. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22(10), 1479-1491 (2007). (Pubitemid 351229318)
24. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 102(4), 433-441 (2006). (Pubitemid 44403162)
25. Bagan JV, Jimenez Y, Diaz JM et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol. 45(7), 645-656 (2009) • Proposal of a new classification of Osteonecrosis of the jaws (ONJ), which if implemented could allow for earlier diagnosis.
26. Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Biphosphonate related osteonecrosis of the jaws: risk factors in breast cancer patients. A case control study. J. Clin. Oncol. 26(28), 4634-4638 (2008). • Clinical study setting the current level of evidence linking dental extractions and use of dentures with ONJ.
27. Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 31(2), 202-206 (2008).
28. Walter C, Al-Nawas B, Grotz KA et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol. 54(5), 1066-1072 (2008).
29. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23(34), 8580-8587 (2005). (Pubitemid 46211499)
30. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg. 65(7), 1328-1331 (2007). (Pubitemid 46915477)
31. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br. J. Haematol. 134(6), 620-623 (2006). (Pubitemid 44253605)
32. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grotz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115(8), 1631-1637 (2009). • Another recent, well-designed clinical study to characterize the complication.
33. Vahtsevanos K, Kyrgidis A, Verrou E et al. Bisphosphonate related osteonecrosis of the jaws: a longitudinal cohort study of risk factors in cancer patients. J. Clin. Oncol. DOI: 10.1200/JCO.2009.21.9584 (2009) (Epub ahead of print). • Very recent study, comparing the most common BPs in a clinical oncology setting in regard to their potencies to induce ONJ.
34. Raje N, Woo SB, Hande K et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin. Cancer Res. 14(8), 2387-2395 (2008). (Pubitemid 351551072)
35. Kyrgidis A, Andreadis C. Clinical characterization might help in preventing osteonecrosis of the jaw. Clin. Cancer Res. 14(24), 8321 (2008).
36. Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Bioscience Hypotheses 2, 34-36 (2009).
37. Landesberg R, Cozin M, Cremers S et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66(5), 839-847 (2008).
38. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br. J. Haematol. 144(5), 667-676 (2009).
39. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41(3), 318-320 (2007).
40. Reid IR. Osteonecrosis of the jaw - who gets it, and why? Bone 44(1), 4-10. (2009).
41. Kyrgidis A, Vahtsevanos K. Increased risk for biphosphonate related osteonecrosis of the jaws in patients wearing overdentures could be attributable to impaired mucosal cell wound healing. J. Oral Maxillofac. Surg. 67(6), 1355-1356 (2008).
42. Thomson AB, Appleman S, Keelan M, Wallace JL. Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa. Dig. Dis. Sci. 48(2), 308-314 (2003). (Pubitemid 36232997)
43. Amagase K, Hayashi S, Nishikawa K, Aihara E, Takeuchi K. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig. Dis. Sci. 52(8), 1879-1889 (2007).
44. de Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335(14), 1016-1021 (1996).
45. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med. 360(1), 89-90 (2009). • A US FDA researcher notes a novel complication of BP.
46. Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J. Surg. Res. 125(2), 189-212 (2005). (Pubitemid 40602392)
47. Kyrgidis A, Triaridis S, Antoniades K. Effects of bisphosphonates on keratinocytes and fibroblasts may have a role in the development of osteonecrosis of the jaw. Bioscience Hypotheses 2(3), 153-159 (2009). • Novel hypothesis on the pathogenesis of ONJ, supported by evidence from a critical review of the literature.
48. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif. Tissue Int. 82(3), 191-201 (2008).
49. Hays PL, Kawamura S, Deng XH et al. The role of macrophages in early healing of a tendon graft in a bone tunnel. J. Bone Joint Surg. Am. 90(3), 565-579 (2008). (Pubitemid 351341991)
50. Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13(15 Pt 1), 4482-4486 (2007). (Pubitemid 47219717)
51. Hashimoto K, Morishige K, Sawada K et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354(2), 478-484 (2007). (Pubitemid 46161348)
52. Heidenreich A, Ohlmann CH. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev. Anticancer Ther. 4(6), 991-1005 (2004). (Pubitemid 39646556)
53. von Knoch F, Jaquiery C, Kowalsky M et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34), 6941-6949 (2005). (Pubitemid 41095518)
54. Pan B, To LB, Farrugia AN et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34(1), 112-123 (2004). (Pubitemid 38142439)
55. Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K, Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFκB pathway in osteosarcoma cells. Br. J. Pharmacol. 146(5), 633-641 (2005). (Pubitemid 41573614)
56. Corso A, Ferretti E, Lunghi M et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104(1), 118-125 (2005). (Pubitemid 40847759)
57. Yu J, Chang SS, Suratwala S et al. Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). J. Orthop. Res. 23(5), 1004-1012 (2005). (Pubitemid 41245422)
58. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63(11), 1567-1575 (2005). (Pubitemid 41525412)
59. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 14(3), 277-285 (2008).
60. Gomez Font R, Martinez Garcia ML, Olmos Martinez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med. Oral Patol. Oral Cir. Bucal. 13(5), E318-E324 (2008).
61. Akintoye SO, Lam T, Shi S, Brahim J, Collins MT, Robey PG. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38(6), 758-768 (2006). (Pubitemid 44500651)
62. Meran S, Thomas DW, Stephens P et al. Hyaluronan facilitates transforming growth factor-β1-mediated fibroblast proliferation. J. Biol. Chem. 283(10), 6530-6545 (2008).
63. van Beurden HE, Snoek PA, Von den Hoff JW, Torensma R, Kuijpers-Jagtman AM. Fibroblast subpopulations in intra-oral wound healing. Wound Repair Regen. 11(1), 55-63 (2003). (Pubitemid 36268609)
64. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62(5), 527-534 (2004). (Pubitemid 38542516)
65. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23(6), 826-836 (2008). (Pubitemid 351768801)
66. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7), 968-971 (2006). (Pubitemid 44023154)
67. Estilo CL, Van Poznak CH, Wiliams T et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13(8), 911-920 (2008). • A clinical study from Memorial Sloan-Kettering Cancer Center, shedding light on many aspects of ONJ.
68. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br. Dent. J. 206(2), 93-98 (2009).
69. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum. 32(2), 94-124 (2002).
70. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 45(6), e38 (2009).
71. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am. J. Med. 121(6), 475-483 e473 (2008). • A NIH-founded systematic review of patients who developed ONJ under BP treatment for non-malignant indications. (Pubitemid 351694348)
72. Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 27(2), 221-226 (2009). • Clinical study conducted in a randomized controlled trial setting, reporting an increased incidence of ONJ among patients who received BP and anti-VEGF treatment.
73. Christodoulou C, Pervena A, Klouvas G et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76(3), 209-211 (2009).
74. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann. Oncol. 19(12), 2091-2092 (2008).
75. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J. Clin. Oncol. 26(24), 4037-4038 (2008).
76. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20(1), 117-120 (2009).
77. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. the experience of the National Cancer Institute of Milan. Ann. Oncol. 20(1), 137-145 (2009).
78. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144(10), 753-761 (2006).
79. Wutzl A, Biedermann E, Wanschitz F et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30(9), 1224-1230 (2008).
80. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J. Craniomaxillofac. Surg. 33(6), 395-403 (2005). (Pubitemid 41644444)
81. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonateassociated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1), 83-93 (2005).
82. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann. Oncol. 17(8), 1197-1204 (2006). (Pubitemid 44288209)
83. Coleman RE. The role of bone markers in metastatic bone disease. Cancer Treat. Rev. 32(Suppl. 1), 1-2 (2006).
84. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. Br. J. Oral Maxillofac. Surg. 67(5 Suppl. 1), 2-12 (2009). • The task-force position of the American Association of Oral and Maxillofacial Surgeons (AAOMS).
85. Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol. Oncol. 26(4), 420-425 (2008).
86. Deal C. Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol. 5(1), 20-27 (2009).
87. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr. Opin. Support Palliat. Care 2(3), 197-203 (2008).
88. Kyrgidis A, Triaridis S. Comment on: bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 45(6), e38 (2009)
89. Kyrgidis A, Andreadis C. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonates osteonecrosis of the jaw in breast cancer patient. Oncologist 14, 101-102 (2009).
90. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N. Engl. J. Med. 359(3), 316-317; author reply 317-318 (2008).
91. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 358(12), 1304-1306 (2008).
92. Lenart BA, Neviaser AS, Lyman S et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int. DOI 10.1007/s00198-008-0805-x (2008) (Epub ahead of print).
93. Stephens R. Metal Fatigue in Engineering (Second edition). John Wiley & Sons, Inc, New York, NY, USA (2001).
94. Wheeless CR. Wheeless' Textbook of Orthopaedics. Van Der Bauwhede J, Sherry E (Eds). (1996)
95. Kyrgidis A, Triaridis S. Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding 'risks and benefits of bisphosphonates'. Br. J. Cancer 100(4), 670 (2009).
96. Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol. 127(5), 998-1008 (2007).
97. Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC, Leung KM. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol. 37(3), 225-233 (2001). (Pubitemid 32245846)
98. Kim SG, Chae CH, Cho BO et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J. Oral Pathol. Med. 35(1), 37-45 (2006).
99. Poulsen RC, Wolber FM, Moughan PJ, Kruger MC. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat. 85(1-2), 42-48 (2008).
100. Boswell BA, Lein PJ, Musil LS. Cross-talk between fibroblast growth factor and bone morphogenetic proteins regulates gap junction-mediated intercellular communication in lens cells. Mol. Biol. Cell 19(6), 2631-2641 (2008).
101. Kajiya H, Ito M, Ohshima H et al. RANK ligand expression in heat shock factor-2 deficient mouse bone marrow stromal/ preosteoblast cells. J. Cell Biochem. 97(6), 1362-1369 (2006).
102. Barling PM, Lai AK, Nicholson LF. Distribution of EGF and its receptor in growing red deer antler. Cell Biol. Int. 29(3), 229-236 (2005).
103. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 16(5), 585-601 (2008).
104. Kyrgidis A, Triaridis S, Vahtsevanos K. New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment. Hippokratia 13(1), 64 (2009).